Excitatory amino acid agonists. Enzymic resolution, X-ray structure, and enantioselective activities of (R)- and (S)-bromohomoibotenic acid.
J J Hansen, B Nielsen, P Krogsgaard-Larsen, L Brehm, E O Nielsen, D R Curtis
Index: J. Med. Chem. 32(10) , 2254-60, (1989)
Full Text: HTML
Abstract
The enantiomers of alpha-amino-4-bromo-3-hydroxy-5-isoxazolepropionic acid (4-bromohomoibotenic acid, Br-HIBO, 1) a selective and potent agonist at one class of the central (S)-glutamic acid receptors, were prepared with an enantiomeric excess higher than 98.8% via stereoselective enzymic hydrolysis of (RS)-alpha-(acetylamino)-4-bromo-3-methoxy-5-isoxazolepropionic acid (4) using immobilized aminoacylase. The absolute configuration of the enantiomers of Br-HIBO was established by X-ray crystallographic analysis, which confirmed the expected preference of the enzyme for the S form of the substrate 4. (S)- and (RS)-Br-HIBO were potent neuroexcitants on cat spinal neurones in vivo, while (R)-Br-HIBO was a very weak excitant. Correspondingly, the S enantiomer of Br-HIBO (IC50 = 0.34 microM) was considerably more potent than the R form (IC50 = 32 microM) as an inhibitor of [3H]-(RS)-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ([ 3H]AMPA) binding to rat brain synaptic membranes in vitro. In contrast, (S)- and (R)-Br-HIBO were approximately equipotent (IC50 values of 0.22 and 0.15 microM, respectively) as inhibitors of [3H]-(S)-glutamic acid binding in the presence of CaCl2. The enantiomers of Br-HIBO showed no significant affinity for those binding sites on rat brain membranes which are labeled by [3H]kainic acid or [3H]-(R)-aspartic acid.
Related Compounds
Related Articles:
Turning behaviour and catalepsy after injection of excitatory amino acids into rat substantia nigra.
1981-05-29
[Neurosci. Lett. 23 , 337, (1981)]
Structural determinants of agonist-specific kinetics at the ionotropic glutamate receptor 2.
2005-08-23
[Proc. Natl. Acad. Sci. U. S. A. 102(34) , 12053-8, (2005)]
Identification of amino acid residues in GluR1 responsible for ligand binding and desensitization.
2001-05-01
[J. Neurosci. 21(9) , 3052-62, (2001)]
1997-11-01
[J. Pharmacol. Exp. Ther. 283(2) , 742-9, (1997)]
1994-07-01
[J. Neurochem. 63(1) , 133-9, (1994)]